Molecular Pathogenesis of Renal Cell Carcinoma: A Review by Israel Gomy & Wilson Araújo Silva Jr.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1 
Molecular Pathogenesis 
of Renal Cell Carcinoma: A Review 
Israel Gomy and Wilson Araújo Silva Jr. 
University of São Paulo, Medical School of Ribeirão Preto,  
Genetics Department, Ribeirão Preto,  
Brazil 
1. Introduction 
Renal cell carcinomas (RCC) represent almost 90% of all kidney cancers and in about 2% of 
cases there is a family history of RCC (McLaughlin et al, 1984). Despite their rare incidences, 
Mendelian hereditary syndromes with RCC have provided important insights into the 
molecular pathogenesis of this tumor. The cloning of susceptibility genes that are involved in 
familial predisposition has offered entry points into the signaling pathways that are 
deregulated in sporadic RCC. Sporadic RCC are extremely heterogeneous and are classified 
into many histolological subtypes. The most frequent form is clear cell or conventional RCC, 
accounting for approximately 75% of all cases, whereas the most common non-clear cell tumor 
is papillary RCC (12% of cases), which is subdivided into types 1 and 2. Other subtypes 
include chromophobe and oncocytomas, each of them occurring in 4% of patients, collecting-
duct (<1%) and rare forms or yet to be classified (< 2%). The correlation between 
histopathological features and genetic alterations in RCC has been introduced in 1997 with the 
Heidelberg classification (Kovacs et al, 1997). More recently, expression profiles through 
microarrays have been done for many of the kidney tumor subtypes and provide the evidence 
that their expression patterns reflect their histological classifications and demonstrate that 
various renal tumor subtypes are genetically distinct entities (Higgins et al, 2003). 
Generally, there is a good correlation between the genetic causes of familial RCC and their 
histopathological features as exemplified by the commonest form of hereditary RCC, von 
Hippel-Lindau (VHL) disease, which invariably presents a clear cell type. Moreover, 
germline mutations in the MET proto-oncogene cause type 1 papillary RCC, whereas type 2 
is correlated with germline mutations in the fumarate hidratase gene, which cause  
hereditary leiomyomatosis. Birt-Hogg-Dubè syndrome is also characterized by susceptibility 
to RCC but with a mixed chromophobe-oncocytoma histopathology, and is associated with 
germline mutations in the BHD tumor suppressor gene.  
All the genes identified so far, which are involved in the molecular pathogenesis of 
hereditary and sporadic RCC comprise a diverse set of complex biochemical and cell 
metabolism pathways, such as iron, energy, nutrient and oxygen-sensing (Linehan et al., 
2010a). A plenty of biochemical and molecular studies of the numerous signalling pathways 
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disrupted in RCC have already provided reasonable translational approaches and clinical 
applications of target therapy RCC with promising results (Iliopoulos, 2006). The 
histopathological and molecular features of RCC are summarized in table 1. 
 
Tumor type Locus Gene Pathway Syndrome 
 
Clear cell  
3p25 
 
3p14 
3p21 
17p11 
VHL 
 
FHIT 
RASSF1A 
BHD 
VEGF 
 
TGF-┚ 
 
AMPK-
mTOR 
von Hippel-Lindau 
 
Familial clear cell 
RCC 
 
Birt-Hogg-Dube 
Papillary 
type 1 
type 2 
 
7q31 
1q42 
 
7q31.1 
9q34 
16p13 
1q25 
 
MET 
FH 
 
FRA7G 
TSC1 
TSC2 
HRPT2 
 
MET-HGF 
VEGF 
TGF-┚ 
 
mTOR 
mTOR 
 
Hereditary papillary 
RCC  
Hereditary 
leiomatosis 
 
 
Tuberous sclerosis 
complex 
Tuberous sclerosis 
complex 
Hyperparathyroidism
-jaw tumor 
Chromophobe 
 
17p11 BHD AMPK-
mTOR 
 
Birt-Hogg-Dube 
Oncocytoma 17p11 
9q34 
16p13 
BHD 
TSC1 
TSC2 
AMPK-
mTOR 
mTOR 
mTOR 
Birt-Hogg-Dube 
Tuberous complex 
Tuberous complex 
Collecting 
duct 
carcinoma 
-1q32,-6p,-8p, 
-9p,-13q,-
19q32,-21q 
 
unknown 
 
unknown 
 
none 
 
Renal 
carcinoma 
associated 
with Xp11.2 
translocation 
 
1p34 
1q21 
17q23 
17q25 
3q23 
Xq12 
 
PSF-TFE3 
PRCC-TFE3 
CTLC-TFE3 
ASPL-TFE3 
? 
NonO-TFE3 
 
 
 
none 
 
 
 
none 
Mucinous 
tubular and 
spindle cell 
carcinoma 
-8p,-9p,-
11q,+12q,+16
q+17,+20q 
 
unknown 
 
unknown 
 
none 
Table 1. Histopathological and genetic characteristics of RCC 
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2. The oxygen-sensing pathway: HIF-VHL interaction and clear-cell RCC 
pathogenesis 
Hypoxia-inducible factors (HIF) are oxygen-sensitive basic helix–loop–helix transcription 
factors, which regulate biological processes that facilitate both oxygen delivery and cellular 
adaptation to oxygen deprivation. HIF is a heterodimer consisting of unstable a-subunits 
and stable constitutively expressed b-subunits. HIF-┙, together with HIF-┚ bind to hypoxia-
response elements in gene promoters to regulate the expression of genes that are involved in 
energy metabolism, angiogenesis, erythropoiesis, iron metabolism, cell proliferation, 
apoptosis and other biological processes. HIF1-┙ and HIF2-┙ mediate transcription of a 
number of downstream genes thought to be important in cancer, including transforming 
growth factor alpha (TGF-┙), platelet-derived growth factor (PDGF), and vascular 
endothelial growth factor (VEGF) (Linehan et al., 2010a). 
In clear-cell renal-cell carcinoma, HIF-┙ accumulates, resulting in the overexpression of 
proteins that are normally inducible with hypoxia, acting on neighboring vascular cells and 
promoting tumor angiogenesis. The augmented tumor vasculature provides additional 
nutrients and oxygen to promote the growth of tumor cells (Cohen & McGovern, 2005). 
Germline mutations in the VHL gene are found in almost all families with VHL disease, an 
autosomal dominant condition characterized by a plenty of benign and malignant tumors 
(Figure 1). The most common cancer is clear cell RCC, which affects 25-30% of patients and 
is a major concern in disease morbity and mortality (Maher et al., 1990). Remarkably, up to  
 
 
 
Fig. 1. von Hippel-Lindau disease predisposes to several tumors in brain, spinal cord, eyes, 
liver, pancreas, kidneys, testes.  
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91% of patients with sporadic clear cell RCC harbor biallelic VHL inactivation (Gnarra et al, 
1994). Somatic mutations are found in approximately 50% of these tumors, whereas 
inactivation due to promoter hypermethylation has been identified in 10-20% of sporadic 
clear-cell RCC (Kim & Kaelin, 2004). Therefore, defects in the VHL gene are the major 
responsible for all cases of RCC. 
The product of the VHL gene, VHL protein (pVHL), is part of an intracellular multiprotein 
complex that contains elongin C and B, Cul2 and Rbx1 and functions as the substrate 
recognition component of an E3-ubiquitin ligase. This complex selects specific substrates for 
ubiquitination and targets them for destruction through the proteasome, mainly HIF-┙. In 
normoxia, the a-subunits are the target for prolyl hydroxylation that generates a binding site 
for pVHL. The interaction between the two proteins causes the polyubiquitynation and 
subsequent proteosomal degradation of HIF-┙. When the cell is hypoxic or iron levels are 
low, the VHL complex cannot target and degrade HIF and HIF overaccumulates, driving the 
transcription of a number of genes important in cancer, such as VEGF, PDGF, and 
GLUT1(Figure 2a). In cells with normal VHL function, the ┙ subunits of HIF are rapidly 
degraded by the proteasome, whereas in VHL-defective cells HIF-┙ subunits are 
constitutively stabilized (Maxwell et al, 1999). When the VHL gene is mutated, as in clear 
cell RCC, the complex cannot target and degrade the ┙ subunits of HIF leading to 
upregulation of their targets genes (Figure 2b). Therefore, the absence of pVHL mimics 
hypoxia and results in a constitutive up-regulation of HIF that produces a transcriptional 
activation of several target genes, such as VEGF, PDGF-B, erythropoietin, TGF-┙, and 
glucose-transporter-1 (GLUT-1). 
 
Fig. 2. The HIF-VHL-VEGF pathway. a. HIF- ┙ degradation in normoxic cells and 
stabilization in hypoxic cells. b. HIF1- ┙ and HIF2- ┙ are not degraded and upregulate the 
expression of their target genes (VEGF, PDGF, GLUT1)(with permission). 
It has been shown that VEGF protein expression in VHL-defective renal cancer cells is mainly 
induced by HIF-2┙ activity. The expression of other HIF targets, such as GLUT-1, urokinase-
type plasminogen activator receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1), 
was also regulated by HIF-2a in these cells. Thus, HIF-2┙ seems to play a critical role in 
tumorigenesis of clear-cell RCC mediated by loss of VHL (Kondo et al, 2002). Clear cell kidney 
cancers (with or without VHL mutation) that express both HIF1-┙ and HIF2-┙ exhibit 
enhanced signaling via the mitogen-activated protein kinase (MAPK) and mTOR pathways. 
Constitutive activation of the Raf/MEK/Erk pathway has been demonstrated in 
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approximately 50% of RCC samples (ref.14. EJC). Conversely, clear cell tumors that express 
only HIF2-┙ have elevated activity of the oncogene c-myc (Gordan et al, 2008).  
VHL substrates other than HIF have been reported, and although their exact role in kidney 
carcinogenesis has not been proved to be the same as HIF’s, it is possible that they may 
contribute directly or indirectly to VHL-deficient RCC and/or other solid tumors. VHL has 
been shown to interact with the RNA polymerase II subunits Rpb1, Rbp6, and Rpb7 at 
domains that present sequence and structural similarity to the HIF binding domain. Binding 
of these subunits to pVHL was shown to promote their ubiquitination and decrease 
transcriptional activity of Pol II (Kuznetsova  et al, 2003). 
Moreover, pVHL has been shown to influence the content of the extracellular matrix. 
Fibronectin coimmunoprecipitates with wild type but not mutant pVHL, and pVHL-
deficient RCC cell lines fail to assemble extracellular fibronectin, most likely because of a 
defect in fibronectin maturation (Ohh et al, 1998). 
Finally, it was recently shown that VHL is linked to the DNA damage response pathway. 
pVHL binds directly to p53, inhibits its mdm2-mediated ubiquitination, suppresses p53 
nuclear export, and promotes its acetylation by p300 and overall p53 transcriptional activity. 
Reintroduction of pVHL in VHL-deficient RCC lines enhances p53-mediated G1 arrest and 
promotes their apoptotic response to genotoxic stress (Roe et al, 2006). 
2.1 Therapeutic perspectives 
The better understanding of VHL signaling pathway has provided the foundation for the 
development of therapeutic approaches that target this pathway in patients with advanced 
clear cell kidney cancer. 
Most therapeutic agents currently approved to treat clear cell kidney cancer target either the 
downstream targets of HiF activity (such as the VEGF receptor) or inhibit mtorC1, which 
provides translational control of HiF1-┙ (Thomas et al., 2006). The responses to these agents 
observed in patients with advanced clear cell kidney cancer is proof of principle that 
targeting the VHL–HIF pathway can induce tumor regression in humans. However, these 
agents target only a small proportion of the downstream genes regulated by HIFs. An 
approach to target HIF transcriptional activity or translation of HIFs themselves—that is, to 
affect all the genes regulated by HIFs—could potentially provide more-effective therapy. 
Targeting the HIF2-┙ pathway is likely to be more successful than solely targeting the HIF1-
┙ pathway. Efforts are currently underway to identify agents that down regulate HIF2-┙-
induced gene expression (Linehan et al., 2010a). Tyrosine kinase receptors trigger activation 
of signal transduction pathways involved in cell proliferation and survival of RCCs (Patel et 
al, 2006). Growth factors, such as VEGF and TGF-a, might bind to the respective tyrosine 
kinase receptors (EGFR and VEGFR-1) that are expressed in renal cancer cells. Thus, these 
receptors could potentially be targets of small molecules inhibitors. Nevertheless, many 
chemotherapeutic and targeted tyrosine kinase approaches are limited by their toxic effects 
on non-tumor cells. An alternative therapy, might be done by targeting autophagy, a central 
component of the cell response to nutrient and energy deprivation (Turcotte et al, 2008). By 
this approach, only those cells with no VHL product would be affected, whereas cells with a 
wild-type copy of the VHL gene would not. Therefore, this would provide a less-toxic and 
more-effective form of therapy for patients with advanced renal cancer. 
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3. The MET-HGF pathway and type-1 papillary renal cancer 
Papillary renal-cell carcinoma occurs in several familial syndromes. Hereditary papillary 
renal carcinoma (HPRC) is an autosomal dominant disorder associated with multifocal 
papillary renal-cell carcinoma with type 1 histological features and is caused by germline 
activating mutations in the MET proto-oncogene (Schmidt et al, 1997) (Figure 3). 
 
Fig. 3. Hereditary Papillary Renal Carcinoma leads to multiple (even thousands) of papillary 
tumors. (with permission) 
The MET proto-oncogene encodes a receptor tyrosine kinase that is physiologically 
activated by hepatocyte growth factor (HGF). Binding of HGF to the extracellular portion of 
the MET receptor triggers autophosphorylation of critical tyrosines in the intracellular 
tyrosine kinase domain, thus activating a downstream signaling cascade. Activation of the 
MET/HGF signaling pathway has been shown to be involved in a number of biological 
activities including cell proliferation, cell motility, branching morphogenesis and epithelial-
mesenchymal transition (Boccaccio & Comoglio, 2006).  
Mutations of the MET proto-oncogene were detected in germline of all HPRC patients but 
only in a small subset of cases with sporadic type 1- papillary RCC (Schmidt et al, 1999). 
Thus, the pathogenesis of hereditary papillary renal carcinoma is usually different from that 
of sporadic papillary RCC. Tumorigenesis of most sporadic papillary RCCs are not be 
induced only by MET mutations, but mostly by MET and chromosome 7-related genes 
dosage. Since the frequency of MET mutations in sporadic papillary RCCs is low, it is 
possible that other genes might be involved in this form of renal cancer. In this respect, 
mutations of the KIT proto-oncogene have been described in 68% of papillary RCC patients 
(Lin et al, 2004). However, the role of KIT in the pathogenesis of this disease needs to be 
confirmed by functional studies. Furthermore, nutrient-stimulated HGF–MET signaling 
induces phosphorylation of serine–threonine protein kinase 11 (STK11or LKB1) through the 
RAS–ERK pathway, implicating MET in the LKB1–AMPK–mTOR nutrient and energy 
sensing pathway (Figure 4). 
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Fig. 4. HGF-MET pathway. Crosslinks between other energy, iron and oxygen-sensing 
pathways. (with permission) 
Of particular interest for renal carcinogenesis is the observation that MET and VHL 
signaling pathways intersect via pVHL-mediated regulation of HIF function. HIF 
stabilization through hypoxia or loss of VHL function results in transcriptional 
upregulation, and therefore promotion of the transforming potential of the c-MET receptor 
(Pennacchietti et al, 2003). This crosstalk between VHL and c-MET pathways may explain 
why clear-cell and papillary histologies often coexist in the same tumor (Iliopoulos et al, 
2006). 
3.1 Therapeutic perspectives 
The therapeutic implications of inhibiting c-MET signaling are promising, as activating 
mutations or copy number–overexpression of c-MET underlies a significant subset of type 1 
papillary RCC.  
A clinical trial is currently underway to determine the effect of foretinib, a kinase inhibitor 
of both MET and VEGF receptors, in patients with either hereditary or sporadic papillary 
kidney cancer. Early evidence shows the efficacy of this agent in patients with germline 
mutations in the tyrosine kinase domain of MET (Srinivasan et al, 2009). Response to such 
an agent with activity against MET might be seen in tumors that are characterized by a 
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mutation in the tyrosine kinase domain of MET; this drug might also have some activity in 
tumors that have MET amplification (Linehan et al., 2010b). 
4. The mitochondrial metabolic pathway: The FH gene and type-2 papillary 
renal cancer and the SDH gene 
Germline mutations of the FH gene, which encodes mitochondrial fumarate hydratase, have 
been detected in most individuals with hereditary leiomyomatosis renal cell carcinoma 
(HLRCC), who are susceptible to develop cutaneous and uterine leiomyomas, uterine 
leiomyosarcoma and, most often solitary and unilateral renal tumors, which may present 
different histological patterns, particularly type-2 papillary RCC (Tomlinson et al, 2002) 
(Figure 5). 
 
Fig. 5. Hereditary Leiomyomatosis Renal Cell Carcinoma predisposes to type-2 papillary 
RCC (left), uterine (middle) and cutaneous (right) leiomyomas (with permission). 
FH is an enzyme component of the mitochondrial tricarboxylic acid or Krebs cycle, which 
has an important role in energy metabolism. In patients with FH deficient cells, it has been 
proposed that the inactivation of this enzyme might lead to a hypoxic environment that can 
favour renal carcinogenesis. FH inactivating mutations increase fumarate levels, and 
consequently the concentration of the fumarate precursor succinate. The high levels of 
succinate in the cytoplasm lead to stabilization of HIF-1┙ subunits and transcriptional 
upregulation of hypoxia-inducible genes, such as VEGF and GLUT1 (which encodes the 
glucose transporter type 1) (Figure 6). Thus, these factors are critically important to increase 
vasculature and glucose transport in RCC cells, thereby contributing to the highly 
aggressive nature of HLRCC-associated renal tumors (Iliopoulos et al, 2006).  
The inhibition of HIF-1┙ by the increased levels of fumarate provides a VHL-independent 
mechanism for dysregulation of HIF degradation in FH-deficient HLRCC-associated kidney 
cancers. FH-deficient kidney cancer cell lines are glucose-dependent and have significantly 
impaired oxidative phosphorylation. The glucose-mediated generation of cellular reactive 
oxygen species in an FH-deficient kidney cancer cell line results in stabilization of HIF1-┙ 
(Sudarshan et al, 2009). The impaired oxidative phosphorylation in FH-deficient kidney 
cancer results in a nearly total dependence on glycolysis for energy production.  
Succinate dehydrogenase (SDH) is another Krebs cycle enzyme gene that has been 
associated with the development of familial tumors. Familial paraganglioma/ 
pheochromocytoma kindreds have been found to have germline mutations in the 
mitochondrial complex II genes SDHB, SDHC, and SDHD. Renal carcinoma, along with 
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pheochromocytoma/paraganglioma, has been found to be a component of the familial 
pheochromocytoma/paraganglioma complex associated with germline SDHB mutations 
(Neumann et al, 2004), and a recent report described germline SDHB mutations in a family 
with renal cancer with no history of pheochromocytoma (Ricketts et al, 2008). The inactivation 
of SDH increases levels of succinate, which has been shown to affect HIF stability (Isaacs et al, 
2005). It would be expected to severely impair oxidative phosphorylation and lead to glucose 
dependence of SDH-deficient kidney tumors, which are likely to be as sensitive to glucose as 
FH-deficient tumors (Linehan et al., 2010a) (Figure 6). 
 
Fig. 6. FH and SDH genes and the metabolic mitochondrial pathway crosslinking with the 
HIF-VHL pathway (with permission). 
4.1 Therapeutic perspectives 
Both enhanced tumor angiogenesis and glucose transport could be the best targets for the 
treatment of either FH-deficient or SDH-deficient renal tumors, because they are extremely 
dependent on glucose transport for energy production. Whereas targeting the vasculature in 
patients with advanced VHL-deficient clear cell kidney cancer has only resulted in modest 
success, targeting the vasculature in both FH and SDH-deficient tumors could provide a 
powerful and effective approach to disrupt the fundamental metabolic machinery of these 
aggressive cancers (Linehan et al., 2010a). 
5. The FLCN gene and chromophobe renal cell carcinomas-oncocytomas 
The FLCN gene is impaired in Birt-Hogg-Dubè syndrome, a rare autosomal dominant 
disorder characterized by hair-follicle hamartomas (fibrofolliculomas) of the face and neck, 
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spontaneous pneumotorax, lung cysts and RCCs, particularly chromophobe RCC (33%), 
hybrid oncocytic renal cell carcinoma (50%), clear-cell RCC (9%) and oncocytomas (5%) (De 
Luca et al, 2008) (Figure 7).  
 
 
Fig. 7. Birt-Hogg-Dubè syndrome. Fibrofolliculomas on the face and bilateral RCC (with 
permission). 
The FLCN gene encodes a protein called folliculin, which has no significant homology to any 
known human protein, although it is highly conserved across species (Nickerson et al, 2002). 
All described germline FLCN mutations are insertions, deletions, nonsense and splice-site 
mutations that predict truncation of the protein (Schmidt et al, 2005). In addition, somatic 
mutations in the second copy of BHD or loss of heterozygosity at the FLCN locus were 
observed in 70% of patients with germline mutations, thus suggesting FLCN to play a role as 
a tumor suppressor gene (Vocke et al, 2005).  
In sporadic cases, somatic mutations are rare, but promoter methylation has been observed, 
indicating the involvement of FLCN in sporadic RCC tumorigenesis (Khoo et al, 2003).The 
function of folliculin has not been completely elucidated yet, but recent findings have 
showed that folliculin interacts with FNIP1, which binds to the 5’ AMP-activated protein 
kinase (AMPK), an energy sensor that negatively regulates mammalian target of rapamycin 
(mTOR) (Baba et al, 2006). When folliculin functions normally, the FLCN–FNIP1–FNIP2 
complex binds to AMPK so FLCN is phosphorylated by a rapamycin-sensitive kinase 
(mTORC1). Conversely, when folliculin is deficient, AKT, mTORC1 and mTORC2 are 
activated, thus stimulating tumorigenesis (Figure 8). These findings suggest a potential role 
of folliculin in regulating the activation of this cell survival pathway. 
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The research in murine models of Birt–Hogg–Dube syndrome would suggest that 
rapamycin analogs such as sirolimus might be potential therapeutic agents against renal 
tumors (Linehan et al, 2010a). 
 
Fig. 8. FLCN interacts with AMPK-mTOR pathway. FLCN deficiency allows activation of 
proto-oncogenes (red circles) (with permission). 
6. The AMPK-mTOR nutrient and energy sensing pathway and Tuberous 
Sclerosis Complex 
Germline mutations in either TSC1 or TSC2 genes lead to the Tuberous Sclerosis Complex, 
an autosomal dominant genodermatosis characterized by multiple hamartomatous lesions 
that affect the skin, retina, brain, lungs and kidneys (Figure 9). 
Eighty percent of children with TSC have renal lesions including benign angiomyolipomas 
(70%), cysts (20%), and oncocytoma (<1%) (Ewalt et al, 1998). Renal angiomyolipomas are 
most often multiple and bilateral, but rarely transform to a malignant tumor (<1%). The 
cumulative renal cancer incidence is 2.2%–4.4% (4,5) and the average age at diagnosis is 28 
years, with occasional early childhood cases (Washecka et al, 1991). The renal abnormalities 
in TSC are unusual in patients that develop epithelial lesions, such as cysts, oncocytomas 
and clear cell, papillary, or chromophobe carcinomas as well as mesenchymal lesions 
(angiomyolipomas), suggesting that TSC genes regulate early differentiation and 
proliferation of renal precursor cells (Henske, 2004).  
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The TSC1 gene encodes hamartin and TSC2 encodes tuberin. Both proteins form a 
heterodimer, which interacts with many cellular pathways, including the AMPK-mTOR 
nutrient and energy sensing pathway. TSC1-TSC2 acts as a GTPase-activating protein 
toward rheb, a ras-family GTPase that activates mMTORC1. GTPase activity of the TSC1–
TSC2 complex on rheb results in inhibition of mTOR activity. TSC1-deficient and TSC2-
deficient tumors exhibit increased phosphorylation of p70s6 kinase, s6 ribosomal protein 
and 4e-BP1, downstream effectors of mtorC1 activation, and readouts for initiation of 
mRNA translation and protein synthesis (Crino et al, 2006). Lack of TSC1–TSC2 inhibition of 
mTOR would presumably also result in HIF accumulation through increased HIF mRNA 
translation by activated mTORC1 (Figure 10). 
 
 
 
 
 
 
 
 
Fig. 9. Tuberous Sclerosis Complex. Hamartomatous lesions on skin (top left), 
hypomelanotic macules (top right), cortical tubers (bottom left) and angiomyolipomas 
(bottom right).  
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Fig. 10. TSC1-TSC2 tumor suppressor complex interacts with AMPK-mTOR nutrient and 
energy sensing pathway (with permission). 
6.1 Therapeutic perspectives 
Currently, there are a number of trials that evaluate the role of sirolimus in patients with 
Tuberous Sclerosis Complex. This agent has been demonstrated to cause the regression of 
angiomyolipomas, through the inhibition of the mTOR signaling pathway. Nevertheless, 
after the treatment was stopped, most renal tumors tended to growth again. In spite of that, 
this study provided the grounds for a molecular approach to the treatment of renal tumors 
associated with the TSC1–TSC2 pathway (Linehan et al., 2010b). 
7. Collecting-duct carcinomas 
Collecting duct carcinomas (CDC) are uncommon and aggressive tumors thought to arise 
from cells of the distal nephron. 
Their genetic defects have not been completely elucidated; however, they have shown 
cytogenetic and molecular alterations different from other renal tumors (Kennedy et al, 1990). 
Nonetheless, some molecular findings suggest that these cancers are heterogeneous and can 
exhibit features similar to more common types of RCC as well as to urothelial carcinoma. 
Genetic studies have shown monosomy of chromosomes 1, 6, 14, 15 and 22 and frequent 
allelic loss of 1q, 6p, 8p, 13q and 21q. Monosomy of 8p has been associated with high stage 
and aggressive behavior and  might be responsible for the poor prognosis of CDC (Fuzesi et 
al, 1992). Loss of heterozygosity (LOH) of 3p is rarely detectable in these tumors, although 
VHL allelic loss has been occasionally reported. Moreover, some studies have found 9p LOH 
in half of CDC cases, whereas other studies have not. Mutations of the RB gene and LOH of 
13q have also been observed in some CDC but its role in the pathogenesis of CDC needs to 
be clarified (Fogt et al, 1998). 
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8. Tubulocystic carcinomas 
The molecular pathogenesis of tubulocystic carcinoma, a rare renal tumor composed of 
tubular and cystic structures, remains poorly understood.  
The genomic defects of tubulocystic carcinoma are similar to those of papillary RCC, as it 
often exhibits trisomy of chromosome 17.  It has been hypothesized that it may represent a 
lowgrade collecting duct carcinoma of the kidney despite the lack of enough citogenetic and 
molecular evidence, such as trisomy of 7, monosomy of 1, 6, 14, 15, and 22, allelic loss on 1q, 
6p, 8p, 13q, and 21q, which are often found in CDC (Yang et al, 2008). 
9. Renal medullary carcinomas 
Renal medullary carcinoma is considered as an aggressive variant of collecting duct 
carcinoma, a rare and rapidly growing tumor of the medulla of kidneys. This tumor is 
frequently seen in young male with African ancestry and carriers of sickle cell trait. In a 
study of nine tumors through comparative genomic hybridization (CGH), eight depicted no 
changes and only one presented monosomy of chromosome 22 (Swartz et al, 2002). 
10. TFE translocation carcinomas family 
Accordingly with the WHO classification of renal tumors (Eble et al, 2004), an entity recently 
defined by chromosomal translocations involving the Xp11.2 region is responsible for about 
one third of renal carcinomas in children and young adults. These cancers resemble clear 
cell RCC and seems to have a benign evolution, even with metastasis, while others may 
behave aggressively. They are also known as the TFE translocation carcinoma family 
(MTTCF) (Tomlinson et al, 1991).  
All translocations result in the production of quimeric proteins containing the TFE3 product 
, such as those from PRCC, ASPL, PSF, and NonO (p54nrb) genes. For instance, translocation 
of Xp to chromosome 1 forms an in-frame fusion of the TFE3 gene on Xp11.2 to a novel gene 
PRCC on chromosome 1(Camparo et al, 2008).  
Because the normal TFE3 protein has a DNA-binding domain, fusion proteins composed of 
this gene product and the ubiquitously expressed PRCC and ASPL proteins result in the 
overexpression of an abnormal transcription factor that causes aberrant expression of 
cellular genes. Another subset of renal tumors are associated with a translocation 
t(6;11)(p21;q12) involving the transcription factor TFEB(Camparo et al, 2008). 
Some gene expression profiling studies indicated a distinct subgroup of tumors. For 
example, TRIM 63 glutathione S-transferase A1 and alanyl aminopeptidase are the main 
differentially expressed genes for MTTCF (Camparo et al, 2008).  
Therefore, the correct classification of these tumors may pose important prognostic and 
therapeutical implications. For instance, tumors with the ASPL-TFE3 translocation 
particularly present at an advanced stage associated with lymph node metastases. In 
addition, some tumors with PRCC-TFE3 fusion have been shown to lack a normal mitotic 
checkpoint control, which may turn them more sensitive to chemotherapeutic agents that 
target microtubules, such as vincristine and paclitaxel (Lopez-Beltran et al, 2010). 
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11. Mucinous tubular and spindle renal cell carcinomas 
These are rare and morphologically distinctive tumors, although they share some features of 
type I papillary RCC.  
The main molecular differences between them have been studied through CGH expression 
microarrays. Two studies found multiple genetic abnormalities in all cases, such as losses of 
chromosomes 1, 4, 6, 8, 9,13, 14, 15, 18 and 22. The major differential diagnosis is papillary 
RCC with solid growth, whose gains of chromosomes 7 and 17 and losses of chromosome Y 
are typical, but lack in mucinous tubular and spindle RCC (Rakozy et al, 2002). 
12. Renal cell carcinomas with sarcomatoid transformation 
Sarcomatoid transformation has been seen in all of the common types of RCC: clear cell, 
papillary, chromophobe and collecting duct, but its specific molecular mechanisms remain 
poorly understood.  
It is hypothesized that the sarcomatoid components of RCCs represent areas of 
dedifferentiation, and it seems that the genomic changes associated with a specific type of 
RCC should be conserved within the dedifferentiated sarcomatoid RCC component. In a 
recent study, the allelic loss profile between clear cell and sarcomatoid components of RCCs 
was compared and showed the same pattern of nonrandom X-chromosome inactivation in 
most cases. The results suggested that both clear cell and sarcomatoid components of RCCs 
are derived from the same progenitor cell. Some other studies suggest a link between 
mutation of the TP53 tumor suppressor gene and sarcomatoid morphology. Major 
differential diagnosis is poorly differentiated urothelial carcinoma of the renal pelvis, which 
presents peculiar genetic profiles, specifically, gains of chromosome 3, 7, 17 and losses of 
9p21 (Lopez-Beltran et al, 2010). 
13. Acquired cystic disease-associated renal tumors 
Interestingly, in kidneys that have developed acquired cystic disease and, consequently, 
resulting in end-stage renal disease, two distinctive types of renal neoplasm have been 
found to occur: ‘acquired cystic disease-associated RCC’ and ‘clear cell papillary RCC’ 
(Cossu-Rocca et al, 2010).  
Acquired cystic disease-associated RCCs are morphologically heterogeneous with abundant 
eosinophilic cytoplasm and variably solid , cribriform, tubulocystic with papillary 
architecture. Chromosomal aberrations have been found in these tumors in few studies, 
such as gains of chromosomes 1, 2, 6, 7, 10 and 17 (Cossu-Rocca et al, 2010).  
Clear cell papillary RCC presents with papillary structures proliferating within cystic 
spaces, both lined by cells with clear cytoplasm. Through interphase FISH analysis, a study 
found all tumors to lack the gains of chromosome 7 and loss of Y, which are peculiar for 
papillary RCC and, in addition, there was no 3p deletion, which is typical of clear cell RCC. 
The other major differential diagnoses are: tubulocystic carcinoma (trisomic for 17 but not 
for 7), chromophobe RCC (multiple chromosomal losses) and oncocytoma (loss of 
chromosome 1) (Lopez-Beltran et al, 2010). 
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14. Thyroid-like follicular renal cell carcinoma  
Recently, there have been reports of an uncommon renal tumor, which had not been 
classified under a known subtype of RCC (Lopez-Beltran et al, 2010). It shows similar 
histology to thyroid follicular carcinoma and seems to affect more often women without 
previous lesions in the thyroid.  
Chromosomal gains of 7q36, 8q24, 12, 16, 17p11-q11, 17q24, 19q, 20q13, 21q22.3, and Xp and 
losses of 1p36, 3, and 9q21-33 were identified through CGH. However, a recent report did 
not found any chromosomal alterations on CGH analysis. It is speculated that thyroid-like 
follicular RCC may represent a unique histological subtype of RCC of low malignant 
potential (Lopez-Beltran et al, 2010). 
15. Conclusion 
Currently, there is sufficient evidence that kidney cancer is essentially a disease of 
dysregulated cellular metabolism (Linehan et al, 2010a).  
Germline mutations in each of the seven genes involved in inherited kidney cancer 
syndromes lead to the dysregulation of at least one metabolic pathway that is mediated by 
oxygen, iron, energy or nutrient sensing (Figure 11). 
 
Fig. 11. The metabolic pathways mediated by the seven tumor suppressor genes mutated in 
hereditary cancer syndromes (with permission) 
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The shared consequence of VHL, FH and SDH mutations is the stabilization of HIFs through 
inactivation of the prolyl-hydroxilase domain, which leads to the transcriptional activation 
of genes that stimulate tumor growth, neovascularization, invasion and metastasis. HIF 
overexpression is also triggered by the upregulation of the mTOR pathway, either through 
inactivating mutations in the tumor suppressor genes TSC1,TSC2 and FLCN, or activating 
oncogenic “signalling pathways”.  
By targeting HIF and its downstream genes, a first-line therapeutic approach to VHL-
deficient renal tumors may be feasible and can also be applied to FH-deficient and SDH-
deficient tumors. To date, novel agents focusing on the VHL pathway have been approved 
for the treatment of patients with advanced kidney cancer (Table 2) (Linehan et al, 2010b). 
Unfortunately, however, most of them occasionally present progression and rarely promote 
long-term complete responses. 
In conclusion, the pursuit of a thorough understanding of the molecular pathogenesis and 
the intricate metabolic pathways of advanced renal cell carcinoma may provide the 
foundation for the development of novel approaches that might possibly increase the 
response and survival rates of patients with this extremely heterogeneous disease. 
 
Histology Gene Drug 
Clear cell VHL Sunitinib, sorafenib, 
bevacizumab, temsirolimus, 
everolimus, axitinib 
Type 1 papillary 
 
MET Foretinib 
Type 2 papillary 
 
FH Targeting VEGF 
Chromophobe 
Oncocytoma 
Hibrid oncocytic 
 
FLCN or BHD Rapamycin 
Angiomyolipoma 
 
TSC1, TSC2 Sirolimus 
Table 2. Targeted therapies for the most common renal cell carcinomas 
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